Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27677191 | 0.98 | KMT2A (0.41) | KMT2APOLBMTNR1AMTNR1BSLC2A1 | |
| Water SCHEMBL20853621 | 0.97 | KMT2A (0.41) | KMT2APOLBMTNR1AMTNR1BSLC2A1 | |
| SCHEMBL5587045 | 0.97 | KMT2A (0.42) | KMT2APOLBMTNR1AMTNR1BSLC2A1 | |
| SCHEMBL2111043 | 0.91 | MTNR1A (0.39) | KMT2APOLBMTNR1AMTNR1BSLC2A1 | |
| SCHEMBL2498356 | 0.86 | MTNR1A (0.59) | KMT2APOLBMTNR1AMTNR1BLMNA | |
| SCHEMBL4143235 | 0.85 | MTNR1A (0.39) | KMT2APOLBMTNR1AMTNR1BLMNA | |
| SCHEMBL917492 | 0.84 | GAA (0.59) | KMT2ASLC2A1ALDH1A1PKMGAA | |
| SCHEMBL4614538 | 0.81 | SLC2A1 (0.37) | KMT2APOLBSLC2A1LMNASMN1; SMN2 | |
| SCHEMBL918087 | 0.78 | SLC2A1 (0.55) | KMT2ASLC2A1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1823998 | 0.78 | THRB (0.44) | ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104076158-B | A kind of test kit for measuring HDL-C | 深圳市新产业生物医学工程股份有限公司 | 2016-08-17 | — | — | CN | claimed |
| US-20020182600-A1 | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques | SMITH JACK V (US) | 2002-12-05 | — | — | US | claimed |
| US-12498366-B2 | Measurement method for fibroblast growth factor-23 by forming immunocomplexes | CANON MEDICAL DIAGNOSTICS CORPORATION (JP) | 2025-12-16 | — | — | US | disclosed |
| EP-3995586-B1 | GLYCOSYLATED PROTEIN ASSAY REAGENT CONTAINING PROTEASE STABILIZER INCREASING REDOX POTENTIAL OF FERROCYANIDE, METHOD FOR ASSAYING GLYCOSYLATED PROTEIN, METHOD FOR PRESERVING GLYCOSYLATED PROTEIN ASSAY REAGENT, AND METHOD FOR STABILIZING GLYCOSYLATED PROTEIN ASSAY REAGENT | NAGASE DIAGNOSTICS CO LTD (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12264356-B2 | Method for determining sensitivity to SGLT2 inhibitor and sensitivity marker for SGLT2 inhibitor | NIHON UNIVERSITY (JP) | 2025-04-01 | — | — | US | disclosed |
| US-12168795-B2 | Method for measuring cholesterol in low-density lipoprotein, measurement reagent, and measurement kit | HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD. (JP) | 2024-12-17 | — | — | US | disclosed |
| US-20240402163-A1 | Method for Measuring Fibroblast Growth Factor-23 and Reagent Therefor | HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-12092637-B2 | Method for measuring fibroblast growth factor-23 and reagent therefor | HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO., LTD. (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-3492600-B1 | METHOD FOR MEASURING GLYCATED HEMOGLOBIN | HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| US-20230358767-A1 | METHOD FOR REDUCING MEASUREMENT ERROR | SEKISUI MEDICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| WO-2023190087-A1 | ENHACEMENT OF ACCURACY WHEN MEASURING HIGH-CREATININE-VALUE SPECIMEN | 東洋紡株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-5328832-A | Hydrolysis of triglycerides, measurement of fatty acids, heat treatment and freeze drying | IATRON LABORATORIES, INC. (JP) | 1994-07-12 | — | — | US | disclosed |
| EP-0337005-B1 | Lyophilizate of an aqueous solution of triglyceride substrate for determination of lipase | IATRON LAB (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5156955-A | Used as enzyme for catalyzing oxidation reaction of nucleoside | OTSUKA FOODS CO., LTD. (JP) | 1992-10-20 | — | — | US | disclosed |
| US-5082769-A | Hydrolysis | IATRON LABORATORIES, INC. (JP) | 1992-01-21 | — | — | US | disclosed |
| EP-0353311-A1 | NUCLEOSIDE OXIDASE AND ANALYTICAL METHOD USING SAME | OTSUKA FOODS CO., LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| EP-0337005-A1 | Lyophilizate of an aqueous solution of triglyceride substrate for determination of lipase | IATRON LABORATORIES, INC. (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0267247-A1 | PROCESS AND REAGENT FOR DETECTING HEART LESIONS OR DISEASES | Roche Diagnostics GmbH (DE) | 1988-05-18 | — | — | EP | disclosed |
| WO-1987006619-A1 | PROCESS AND REAGENT FOR DETECTING HEART LESIONS OR DISEASES | BOEHRINGER MANNHEIM GMBH (DE) | 1987-11-05 | — | — | WO | disclosed |
| EP-0243901-A1 | Process and reagent for the detection of heart lesions or heart diseases | Roche Diagnostics GmbH (DE) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230358767-A1 | METHOD FOR REDUCING MEASUREMENT ERROR | CAT, MPO, UCHL1 | KMT2A 1904/4885POLB 595/4885MTNR1A 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.